Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laborit study of sodium oxybate for lorazepam-nonresponsive catatonia
ISRCTN11236443Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in catatonia comparing Continued high-dose lorazepam with Sodium oxybate after lorazepam reduction (2 arms). Primary endpoint: Response rate after 4 days of randomized treatment. Started Sep 2024; status: recruiting.
02
Drugs
sodium oxybatelorazepam
03
Conditions
catatonia
Beyond the preview
Go deeper on ISRCTN11236443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11236443.